Andrew Zelenetz, MD, PhD as special coach for the FIL cantera "Indolent B Cell Lymphoma"

Lecce, 4-5-6 May 2016
Laboratorio D.R.e.A.M., palazzina Uffici Amministrativi
Ospedale "Vito Fazzi"
piazza F. Muratore 1 – 73100 Lecce

Tuesday, May 3

7:00 pm – "The coach meets the players".

Opening of the Team training session and dinner.

Wednesday, May 4 Session I

9:00 am – 10:30 am –Overview of indolent B cell lymphoma and Mechanism of therapy

- 1. Diseases to be addressed including aspects of epidemiology, pathology and pathogenesis, natural history
 - a. Follicular lymphoma (FL)
 - b. Marginal zone lymphoma (MZL)
 - i. Extranodal (ENMZL)
 - ii. Splenic (SMZL)
 - iii. Nodal (NMZL)
 - c. Mantle cell lymphoma (MCL)
 - d. Small lymphocytic leukemia
 - e. Hairy cell leukemia
 - f. Waldenström's macroglobulinemia
 - g. Others splenic lymphomas
- 2. Introduction to the mechanism of action of key agents in the management of indolent lymphoma
 - a. Antibodies
 - i. Naked anti-CD20 antibodies
 - ii. Radioimmunotherapy
 - iii. Immunoconjugates
 - b. Pathway inhibitors
 - c. PI3K inhibitors
 - d. BTK inhibitors
 - e. BH3 mimetics
 - f. Checkpoint inhibitors

10:30 am – 11:00 am – Diagnosis and evaluation of patients with indolent lymphoma:

- 1. General diagnosis and evaluation:
 - a. What the physician needs to know
 - b. What the patient needs to know

11:00 am - 11:30 am - Coffee Break

11:30 am - 1:00 pm - Focus on FL

- 1. Approaching the newly diagnosed patient with FL
 - a. Prognostic models (FLIPI, m7 FLIPI, GEP)
 - b. Is treatment always necessary at diagnosis?
 - c. Selection of initial therapy
 - i. Conventional immune-chemotherapy
 - ii. Lenalidomide, an emerging option
 - d. Role of maintenance therapy
 - e. Response evaluation, the role of PET

1:00 pm - 2:00 pm - Buffet lunch

Session II

2:00 pm - 3:00 pm - Focus on MZL

- 1. MZL is a family of related but distinct entities
 - a. ENZML
 - i. Gastric MALT lymphoma, an example of an antigenically driven disease
 - ii. Gastric MALT factors influencing the selection of therapy: antibiotics v radiation
 - iii. Isolated ENMZL, the exception to rule in lymphoma that "surgery is not therapeutic in lymphoma" vs radiation
 - iv. Systemic therapy for ENZML
 - b. SMZL
 - i. Rituximab v Splenectomy
 - c. Nodal marginal zone lymphoma
 - i. Management similar to FL

3:00 pm - 4:00 pm - Focus on MCL

- 1. Prognostic models and the importance of proliferation index (PI)
 - a. MIPI
 - b. Proliferation signature identified by GEP
 - c. Ki-67/MIB-1 as a surrogate for PI
- 2. Distinguishing indolent and typical (aggressive) MCL
 - a. Clinical presentation

- b. Pl
- c. SOX11, IGHV mutation
- 3. Typical MCL, first line management
 - a. Fit, "go-go" candidate for HDT/ASCR
 - b. Unfit, "slow-go" patient
- 4. Role of maintenance in MCL
- 4:00 pm 4:30 pm coffee break
- 4:30 pm 5:30 pm: Management of MCL in relapse
- 5:30 pm 6:30 pm: Transformation in indolent lymphoma
- 8:00 pm Dinner altogether

Thursday, May 5 Session III

9:00 am - 11:00 am - Recurrent indolent lymphoma (non-MCL)

- 1. Conventional therapy
- 2. Role of transplant
- 3. New and investigational drugs
 - a. What is a rational combination?
- 4. Is there a role for "precision medicine" in indolent lymphoma
- 11:00 am 11:30 am coffee break
- 11:30 am 12:00 pm MRD and Tumor Sequencing
 - 1. Measurement of MRD
 - 2. Is there a role for "precision medicine" in indolent lymphoma
- 12:00 pm 1:00 pm Challenges in clinical management of indolent lymphoma
 - 1. Viral reactivation: Hepatitis B, Hepatitis C and PML
 - 2. Management of hypogammaglobulinemia induced by long-term or repeated anti-CD20 therapy
- 1:00 pm 2:00 pm Buffet lunch

Session IV

2:00 – 4:00 pm - Case reports (suggested by the teacher and by the trainees)

- 1. Some possible cases:
 - a. Young patient with FL
 - b. FL/MCL in situ
 - c. Pediatric FL

- d. Blastic transformation of MCL
- e. Composite lymphoma

4:00 pm - 4:30 pm - coffee break

Session V

4:30 pm – 6:30 pm - The Trainees will develop (in small groups) the proposals that will be presented In Session VI on Friday, May 6. (The coach is out during this session)

8:00 pm - Dinner all together

Friday, May 6 Session VI

8:45 am – 9:45 am - "Trainees dreams and proposals": each group of trainees have 7-10 minutes at their disposal to present to the assembly a proposal that they put together during the training, an idea on a issue they would like to investigate on if they had the possibility to access a research excellence center (in the way they prefer, a talk, a slide presentation, etc..)

9:45 am – 10:15 am – Coach Zelenetz evaluates the proposal presented by the trainees, and chooses the one he believes is the more interesting and that would possibly be worth of further elaboration (trainees are out)

10:15 am - 10:30 am - coffee break

10:30 am – 11:15 am - "The winner is...?" : discussion of presented proposals. Coach Zelenetz announces the winner